SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Ronckers Cecile M.)
 

Sökning: WFRF:(Ronckers Cecile M.) > Risk of Soft-Tissue...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00006895naa a2200793 4500
001oai:lup.lub.lu.se:ffaaca2a-fb8a-4e3e-b9d9-1f7fd6ca922a
003SwePub
008180508s2018 | |||||||||||000 ||eng|
0247 a https://lup.lub.lu.se/record/ffaaca2a-fb8a-4e3e-b9d9-1f7fd6ca922a2 URI
0247 a https://doi.org/10.1093/jnci/djx2352 DOI
040 a (SwePub)lu
041 a engb eng
042 9 SwePub
072 7a art2 swepub-publicationtype
072 7a ref2 swepub-contenttype
1001 a Bright, Chloe Ju University of Birmingham4 aut
2451 0a Risk of Soft-Tissue Sarcoma Among 69 460 Five-Year Survivors of Childhood Cancer in Europe
264 c 2017-11-20
264 1b Oxford University Press (OUP),c 2018
300 a 12 s.
520 a Background: Childhood cancer survivors are at risk of subsequent primary soft-tissue sarcomas (STS), but the risks of specific STS histological subtypes are unknown. We quantified the risk of STS histological subtypes after specific types of childhood cancer.Methods: We pooled data from 13 European cohorts, yielding a cohort of 69 460 five-year survivors of childhood cancer. Standardized incidence ratios (SIRs) and absolute excess risks (AERs) were calculated.Results: Overall, 301 STS developed compared with 19 expected (SIR = 15.7, 95% confidence interval [CI] = 14.0 to 17.6). The highest standardized incidence ratios were for malignant peripheral nerve sheath tumors (MPNST; SIR = 40.6, 95% CI = 29.6 to 54.3), leiomyosarcomas (SIR = 29.9, 95% CI = 23.7 to 37.2), and fibromatous neoplasms (SIR = 12.3, 95% CI = 9.3 to 16.0). SIRs for MPNST were highest following central nervous system tumors (SIR = 80.5, 95% CI = 48.4 to 125.7), Hodgkin lymphoma (SIR = 81.3, 95% CI = 35.1 to 160.1), and Wilms tumor (SIR = 76.0, 95% CI = 27.9 to 165.4). Standardized incidence ratios for leiomyosarcoma were highest following retinoblastoma (SIR = 342.9, 95% CI = 245.0 to 466.9) and Wilms tumor (SIR = 74.2, 95% CI = 37.1 to 132.8). AERs for all STS subtypes were generally low at all years from diagnosis (AER < 1 per 10 000 person-years), except for leiomyosarcoma following retinoblastoma, for which the AER reached 52.7 (95% CI = 20.0 to 85.5) per 10 000 person-years among patients who had survived at least 45 years from diagnosis of retinoblastoma.Conclusions: For the first time, we provide risk estimates of specific STS subtypes following childhood cancers and give evidence that risks of MPNSTs, leiomyosarcomas, and fibromatous neoplasms are particularly increased. While the multiplicative excess risks relative to the general population are substantial, the absolute excess risk of developing any STS subtype is low, except for leiomyosarcoma after retinoblastoma. These results are likely to be informative for both survivors and health care providers.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
7001 a Hawkins, Mike Mu University of Birmingham4 aut
7001 a Winter, David Lu University of Birmingham4 aut
7001 a Alessi, Danielau University of Turin4 aut
7001 a Allodji, Rodrigue S4 aut
7001 a Bagnasco, Francesca4 aut
7001 a Bárdi, Edit4 aut
7001 a Bautz, Andrea4 aut
7001 a Byrne, Julianne4 aut
7001 a Feijen, Elizabeth A M4 aut
7001 a Fidler, Miranda M4 aut
7001 a Garwicz, Stanislawu Lund University,Lunds universitet,Sena effekter efter barncancerbehandling,Forskargrupper vid Lunds universitet,Late effects after childhood cancer treatment,Lund University Research Groups,Skåne University Hospital4 aut0 (Swepub:lu)st6750ga
7001 a Grabow, Desiree4 aut
7001 a Gudmundsdottir, Thorgerdur4 aut
7001 a Guha, Joyeeta4 aut
7001 a Haddy, Nadia4 aut
7001 a Jankovic, Momcilo4 aut
7001 a Kaatsch, Peter4 aut
7001 a Kaiser, Melanie4 aut
7001 a Kuehni, Claudia E4 aut
7001 a Linge, Helenau Lund University,Lunds universitet,Sena effekter efter barncancerbehandling,Forskargrupper vid Lunds universitet,SEBRA Sepsis and Bacterial Resistance Alliance,Masspektrometri,Sektion V,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,BioMS,Late effects after childhood cancer treatment,Lund University Research Groups,Mass Spectrometry,Section V,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)medk-hjo
7001 a Øfstaas, Hilde4 aut
7001 a Ronckers, Cecile M4 aut
7001 a Skinner, Roderick4 aut
7001 a Teepen, Jop C4 aut
7001 a Terenziani, Monica4 aut
7001 a Vu-Bezin, Giao4 aut
7001 a Wesenberg, Finn4 aut
7001 a Wiebe, Thomasu Lund University,Lunds universitet,Pediatrik, Lund,Sektion V,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Sena effekter efter barncancerbehandling,Forskargrupper vid Lunds universitet,Paediatrics (Lund),Section V,Department of Clinical Sciences, Lund,Faculty of Medicine,Late effects after childhood cancer treatment,Lund University Research Groups,Skåne University Hospital4 aut0 (Swepub:lu)pedi-twi
7001 a Sacerdote, Carlotta4 aut
7001 a Jakab, Zsuzsanna4 aut
7001 a Haupt, Riccardo4 aut
7001 a Lähteenmäki, Päivi4 aut
7001 a Zaletel, Lorna Zadravecu Institute of Oncology, Ljubljana4 aut
7001 a Kuonen, Rahelu Swiss Childhood Cancer Registry4 aut
7001 a Winther, Jeanette Fu Danish Cancer Society4 aut
7001 a de Vathaire, Florentu Centre for Research in Epidemiology and Population Health (CESP)4 aut
7001 a Kremer, Leontien Cu Princess Maxima Center for Pediatric Oncology/Hematology4 aut
7001 a Hjorth, Larsu Lund University,Lunds universitet,Pediatrik, Lund,Sektion V,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Sena effekter efter barncancerbehandling,Forskargrupper vid Lunds universitet,Paediatrics (Lund),Section V,Department of Clinical Sciences, Lund,Faculty of Medicine,Late effects after childhood cancer treatment,Lund University Research Groups,Skåne University Hospital4 aut0 (Swepub:lu)pedi-lhj
7001 a Reulen, Raoul Cu University of Birmingham4 aut
7102 a University of Birminghamb University of Turin4 org
7102 a PanCareSurFup Consortium
7730 t Journal of the National Cancer Instituted : Oxford University Press (OUP)g 110:6q 110:6x 1460-2105x 0027-8874
8564 u http://dx.doi.org/10.1093/jnci/djx235x freey FULLTEXT
8564 u https://academic.oup.com/jnci/article-pdf/110/6/649/25041826/djx235.pdf
8564 8u https://lup.lub.lu.se/record/ffaaca2a-fb8a-4e3e-b9d9-1f7fd6ca922a
8564 8u https://doi.org/10.1093/jnci/djx235

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy